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Cholesterol recognition amino acid consensusHuman ABCG2 is a plasmamembrane glycoprotein causingmultidrug resistance in cancer. Membrane cholester-
ol and bile acids are efﬁcient regulators of ABCG2 function, while themolecular nature of the sterol-sensing sites
has not been elucidated. The cholesterol recognition amino acid consensus (CRAC, L/V-(X)(1–5)-Y-(X)(1–5)-R/K)
sequence is one of the conserved motifs involved in cholesterol binding in several proteins. We have identiﬁed
ﬁve potential CRAC motifs in the transmembrane domain of the human ABCG2 protein. In order to deﬁne their
roles in sterol-sensing, the central tyrosines of these CRACs (Y413, 459, 469, 570 and 645) were mutated to S
or F and the mutants were expressed both in insect and mammalian cells. We found that mutation in Y459
prevented protein expression; the Y469S and Y645S mutants lost their activity; while the Y570S, Y469F, and
Y645F mutants retained function as well as cholesterol and bile acid sensitivity. We found that in the case of
the Y413S mutant, drug transport was efﬁcient, while modulation of the ATPase activity by cholesterol and
bile acids was signiﬁcantly altered. We suggest that the Y413 residue within a putative CRAC motif has a role
in sterol-sensing and the ATPase/drug transport coupling in the ABCG2 multidrug transporter.
© 2014 Published by Elsevier B.V.1. Introduction
ABCG2 is a plasma membrane glycoprotein in the ABC (ATP Binding
Cassette) family of proteins that are characterized by a unique nucleo-
tide binding/hydrolyzing domain (NBD) and hydrophobic membrane
spanning sequences (transmembrane domain, TMD),mediating ATPase
activity and the recognition and translocation of transported substrates,
respectively. Several ABC transporters, called multidrug resistance
(MDR) proteins, extrude various chemically unrelated compounds
from the cells by utilizing the energy of ATP hydrolysis. ABCG2 is an
MDR half transporter, harboring only a single NBD and a single TMD,
andmust at least homodimerize to exert its proper transporter function
[1–3].
ABCG2 is expressed in many tissues, most abundantly in organs
displaying barrier functions (brain, placenta, and intestine) where itgnition amino acid consensus;
l; GC, glycocholate; HRP, horse-
ffered saline; RAMEB, randomly
amptothecin; TC, taurocholate;
, Research Centre for Natural
k körútja 2., H-1117 Budapest,
czka).inﬂuences the passage of hydrophobic or slightly negatively charged
molecules, including numerous drugs and food constituents. Therefore,
ABCG2 can signiﬁcantly inﬂuence the ADME-Tox (Absorption, Distribu-
tion, Metabolism, Excretion and Toxicity) properties of drugs, especially
the absorption from the intestine, penetration to the central nervous
system through the blood–brain barrier, or the elimination from the
liver or kidney [3–6]. Optimal activity of ABCG2 has been shown to be
important in the regulation of serum urate levels, and polymorphic
ABCG2 variants with decreased function or expression were shown
to be associated with a higher risk of gout [7–9]. Human ABCG2 is
expressed in stem cells of various origins, where it provides a protective
role under hypoxic conditions [10]. Overexpression of ABCG2 confers
multidrug resistance to cancer cells [11–13].
We and others have shown that both the ATPase and the transport
activity of ABCG2 are signiﬁcantly accelerated by cholesterol enrich-
ment of “cholesterol poor” insect cell membranes; whereas cholesterol
depletion of mammalian cells results in decreased ABCG2 function [14,
15], implying that cholesterol is a major modulator of ABCG2 function.
Subsequent studies have shown that functional reconstitution of
puriﬁed ABCG2 requires cholesterol, suggesting that cholesterol is in
fact essential for ABCG2 activity [16].
The mechanisms by which cholesterol-ABCG2 interactions translate
into the observed changes of function, or the site(s) involved in choles-
terol-sensing have not been deﬁned. There is no experimental evidence
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ABCG2 recognizes cholesterol as a transported substrate, as shown for
some related ABCG transporters [17,18]. More probably, cholesterol is
an allosteric modulator of the transporter, or may also have an indirect
effect through inﬂuencing the biophysical properties of the lipid bilayer.
Previous studies have suggested that single amino acids can inﬂu-
ence cholesterol-sensing of ABCG2. Mutation of R482 to small amino
acids (D, G, N, S, T) was shown to alter the cholesterol sensitivity [19];
mutation of the leucines in the LxxL motif (potential steroid binding
element (aa 555–558 [20]) resulted in an apparent cholesterol in-
sensitivity of ABCG2 in Sf9 membranes [19]. While these results
may suggest that the mutated amino acids directly participate in
cholesterol binding, they are not part of any knownmotifs that char-
acterize dedicated cholesterol binding regions. Many proteins that
interact with cholesterol possess an amino acid consensus sequence
termed “CRAC” (cholesterol recognition amino acid consensus) with
the pattern (L/V-(X)(1–5)-Y-(X)(1–5)-R/K). The CRAC sequence was
shown to be an essential determinant of cholesterol recognition in
the peripheral-type benzodiazepine receptor, caveolin, the gp41
protein of the HIV virus, or an integral outer mitochondrial mem-
brane translocator protein [21–24]. The length of a CRACmotif varies
between 5 and 13 amino acids, however, only the ﬁrst and last amino
acids and the central tyrosine residue are conserved. Various muta-
tional studies of the CRAC motifs of cholesterol binding proteins
and cholesterol-regulated ion channels have demonstrated the cru-
cial role of the central tyrosine in cholesterol binding [22,23,25].
Given the modulatory effects of cholesterol on ABCG2 activity, we
screened the amino acid sequence of the protein for CRAC motifs. We
have identiﬁed ﬁve putative CRAC sequences, and changed the central
tyrosines to deﬁne the role of each of these motifs in cholesterol-
sensing. Here we show that the CRACmotif containing tyrosine at posi-
tion 413 in transmembrane helix 1 is involved in sterol-sensing and the
modulation of ATPase/transport coupling of the ABCG2 transporter.
2. Experimental procedures
2.1. Materials
Cholesterol-RAMEB (randomly methylated β-cyclodextrin) was a
kind gift from Cyclolab Hungary. All other chemicals were purchased
from Sigma (Sigma Aldrich, Hungary) unless stated otherwise.
2.2. Plasmid constructs
For the expression of ABCG2 mutants in insect cells, baculovirus
plasmids containing the appropriatemutant ABCG2 cDNAswere gener-
ated by PCR mutagenesis as described earlier [26]. The list of primers
used for mutagenesis is provided in the “Supplementary material”.
The PCR products were digested with PstI and NcoI enzymes and were
ligated into the corresponding sites of the pAcUW21-L/wtABCG2 plas-
mid [27]. The base order of the constructswas conﬁrmedby sequencing.
The generation of the vector construct with the ABCG2-K86M mutant
was described earlier [26].
The plasmids for stable expression in mammalian cell lines were
created by the ligation of the appropriate fragments from pAcUW21-
L/ABCG2-Tyr mutant between the NotI-BamHI sites of the pSB-CMV-
wtABCG2 plasmid [28].
2.3. Cells and cell lines
Sf9 cells (Invitrogen, Life technologies) were grown in TNM-FH in-
sect cell medium complemented with 10% FBS and 100 μg/ml penicil-
lin/100 U/ml streptomycin at 27 °C. HEK 293 cells were cultured in D-
MEM medium containing 10% FBS and 100 μg/ml penicillin/100 U/ml
streptomycin and 5 mM glutamine at 37 °C in 5% CO2.2.4. Generation of insect cells expressing ABCG2-Tyr mutants
Sf9 cells were co-transfected with 250 ng linearized baculovirus
DNA+250 ng baculovirus plasmid DNA using the BaculoGold transfec-
tion kit following the protocol provided by the supplier (BD Biosci-
ences). The presence of the engineered mutations was veriﬁed by
restriction endonuclease digestion of the PCR-ampliﬁed ABCG2 DNA.
2.5. Generation of HEK 293 cells stably overexpressing human ABCG2 and
its Tyr mutants
Cells were transfected using 3 μl Fugene6 reagent (Promega) and
500 ng of the Sleeping Beauty pSB-ABCG2 plasmid DNA and 500 ng
plasmid coding a transposase [29]. 48 h post transfection the cells
were cultured in 1 μg/ml puromycin for 14 days. Cells overexpressing
the highest amounts of the appropriate ABCG2 variant were sorted
based on 5D3 labeling using a FACSAria cell sorter (Becton Dickinson).
In cholesterol depletion experiments we used the HEK 293 cell line
stably expressing the R482G mutant established earlier [15].
2.6. Membrane preparation
Isolation of membranes from Sf9 cells expressing human ABCG2 or
its Tyr mutants and the determination of membrane protein concentra-
tions by the modiﬁed Lowry method were performed as described pre-
viously [30]. Besides control membranes prepared from untreated Sf9
cells, cholesterol pre-loaded membranes were also generated by co-
incubation of the membranes with 0.25, 0.5, 1 or 2 mM cholesterol-
RAMEB at 0 °C for 30 min prior to the ﬁnal ultracentrifugation step of
the membrane preparation procedure [15].
2.7. Detection of ABCG2 by Western blotting
Sf9 membranes or intact HEK 293 cells were suspended in sample
loading buffer (62.5 μM Tris HCl pH 6.8, 2% SDS, 10 μM EDTA-Na
pH 6.8, 10% glycerol, 2 M urea, 0.14 mg/ml bromophenol blue, 100 μM
dithiothreitol). Protein samples were separated on 7.5% Laemmli gels.
Western blot analysis was performed as described earlier [26], by
using the BXP-21 monoclonal antibody in a 2,000× dilution, and a
goat anti-mouse HRP-conjugated secondary antibody (10,000× dilu-
tion, Jackson Immunoresearch).
2.8. BXP-21 or 5D3 labeling
5 × 105 HEK 293 cells were incubated in 1 ml HPMI buffer (120mM
NaCl, 5 mM KCl, 400 μM MgCl2, 40 μM CaCl2, 10 mM Hepes, 10 mM
NaHCO3, 10 mM glucose and 5 mM Na2HPO4 pH 7.4), containing 0.5%
bovine serum albumin and 1 μg/ml 5D3 antibody for 30 min at 37 °C
in the presence of 1 μMKo143. After washing, the cells were further in-
cubated with a secondary, phycoerythrin-conjugated anti-mouse anti-
body (Molecular Probes, 2 μg/ml). Fluorescence was analyzed in an
Attune focusing ﬂow cytometer (Applied Biosystems).
When Sf9 membranes were labeled with anti-ABCG2 antibodies,
90 μg membranes were incubated with BXP-21 (100× dilution) or
5D3 (ﬁnal concentration 2 μg/ml) antibody in a buffer containing
40 mMMOPS-Tris, 50 mM KCl and 500 μM EGTA-Tris for 30 min at 37
°C, and after washing, with phycoerythrin-conjugated goat anti-mouse
antibody (ﬁnal concentration 1 μg/ml) for additional 30 min at 37 °C.
Fluorescencewas analyzed in a FACSCalibur cytometer (BDBiosciences)
[15,31].
2.9. ATPase assay
Measurement of ATP hydrolysis was performed as described earlier
[27]. The concentrations of test compounds used in the different exper-
iments are indicated in the ﬁgure legends. Basal or drug-stimulated
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cess cholesterol. For the calculation of the KA values, the datawere ﬁtted
with a non-linear dose response curve using the Origin 8.6 software.
2.10. Vesicular uptake assay
The accumulation of 50 μM 3H-methotrexate in inside-out mem-
brane vesicles was measured for 10 min at 37 °C, and the transport re-
action was terminated by rapid ﬁltration [32]. ATP-dependent
transport was determined by subtracting the transport measured in
the absence of MgATP from that of measured in the presence of 4 mM
MgATP.
2.11. Cellular uptake of Hoechst 33342, BODIPY-prazosin, Pheophorbide A
and mitoxantrone
Accumulation of 1 μMHoechst 33342, 20 nMBODIPY-prazosin, 2 μM
Pheophorbide A or 5 μMmitoxantrone was measured as described ear-
lier [26]. Brieﬂy, 5 × 105 HEK 293 cells were co-incubatedwith the given
compound at 37 °C for 20 (Hoechst 33342 and BODIPY-prazosin) or 30
(Pheophorbide A and mitoxantrone) min. The reaction was terminated
by the addition of ice-cold PBS. After centrifugation at 100 g for 5min at
4 °C, the cells were suspended in 1 ml PBS containing 1.25 μg/ml
propidium iodide and intracellular ﬂuorescencewasmeasured in an At-
tune (Hoechst 33342 and BODIPY-prazosin) or a FACSCalibur (Pheo-
phorbide A and mitoxantrone) cytometer. In the case of Hoechst
33342, cellular ﬂuorescence “transport factor” was calculated as fol-
lows: (F100− F0) / F100 × 100, where F0 is the ﬂuorescence (geomean
values) of Hoechst 33342 in the absence of an inhibitor; F100 is the ﬂuo-
rescence (geomean values) in the presence of 1 μM Ko143.
2.12. Cholesterol depletion
1 × 106 HEK 293 cells were incubated with 0.9 ml 4 mM empty
RAMEB diluted in HPMI for 30 min at 37 °C. Then RAMEB was removed
by centrifugation at 700 g for 5min at room temperature, and the trans-
port experiment was performed as described in Section 2.11.
2.13. Determination of doxorubicin efﬂux
5 × 105 HEK 293 cells were incubated with 5 μM doxorubicin in a
ﬁnal volume of 100 μl for 30min at 37 °C in the presence or the absence
of 1 μM Ko143. After washing the cells with 1 ml HPMI, the cells were
further incubated in 100 μl HPMI with or without 1 μM Ko143 for
30 min at 37 °C. The reaction was stopped by washing the cells with
1 ml ice-cold PBS. After centrifugation at 100 g for 5 min at 4 °C, the
cells were suspended in 1 ml PBS containing 1.25 μg/ml propidium io-
dide and intracellular ﬂuorescence was measured in an Attune ﬂow
cytometer at Ex/Em= 488 nm/574 nm.
2.14. Cytotoxicity assay
3 × 103 HEK 293 cells were seeded on ﬂat bottom 96-well plates and
were left to adhere. Next day, cells were treated and were further incu-
bated with the indicated drug for 72 h. The supernatant was then re-
moved and 100 μl 5% PrestoBlue (Life Technologies) was added to the
cells. After incubation at 37 °C, 5% CO2 for 1.5 hours, metabolized
PrestoBlue was measured in a Perkin Elmer Victor X3 2030 Multilabel
Plate Reader at 540 nm excitation and 579 nm emission wavelengths.
2.15. Statistical analysis of data
Statistical signiﬁcance was assessed using paired Student's t-test.3. Results
3.1. Identiﬁcation of potential CRAC motifs
Cholesterol sensor motifs are located in or near the membrane
plane; therefore we restricted our analysis to the transmembrane do-
main of ABCG2. We identiﬁed ﬁve putative CRAC motifs in ABCG2
(Fig. 1). Alignment of the corresponding regions of the human ABCG
proteins revealed that three out of the ﬁve identiﬁed CRAC motifs are
also present in other members of the human ABCG family (see Fig. 1,
inset). The putative CRAC motifs identiﬁed in the sequence of human
ABCG2 are also present in ABCG2 homologs. The 1st CRAC motif (aa
407–418) is conserved amongst mammals (with the exception of
rhesus monkey), but is absent in chicken, or lower species. The 2nd
and 3rd potential CRAC motifs (aa 454–465 and 466–473, respectively)
can be found even in various ﬁsh, e.g. Atlantic salmon or Rainbow
trout; the 4th and 5th putative CRAC motifs (aa 564–575 and 641–647,
respectively) are conserved amongst vertebrates.
3.2. Expression and ATPase activity of ABCG2 CRAC mutants in Sf9 insect
cells
To analyze whether the putative CRAC motifs of ABCG2 inﬂuence
cholesterol-sensing, we mutated the central tyrosines (Y413, 459, 469,
570 and 645) to Ser. The mutant proteins were expressed in Sf9 insect
cells for functional measurements. All but one of the ABCG2 mutants
were successfully expressed in Sf9 insect cells. Mutation of Y459 to S
prevented the expression of the protein, precluding this mutant from
further analysis (Fig. 2A).
Transport of substrates by ABCG2 is coupled to the hydrolysis of ATP.
Measurement of the ATPase activity of the transporter is a well-
established tool for the characterization of the activity of variousmutant
protein variants as well as for the screening of potential ABCG2-
interacting compounds [5]. In order to determine the functionality and
the cholesterol dependence of the CRAC mutant ABCG2 proteins, we
measured their ATP hydrolytic capacity in isolated Sf9 insect cell mem-
branes. We found that mutation of Tyr to Ser at position 469 or 645 re-
sulted in the loss of ATP hydrolysis (even if the activity is corrected for
the lower expression level of the Y469S mutant); while mutations in
the other two positions apparently did not alter ABCG2 functionality,
as both the Y413S and Y570Smutants showed a high level of ATPase ac-
tivity, which could be inhibited by a general ATPase inhibitor vanadate
or the speciﬁc ABCG2 inhibitor Ko143 (Fig. 2B).
In order to test if the inactivity of the Y469S and Y645Smutants was
due to a speciﬁc loss of Tyr at this position, we also mutated these tyro-
sines to phenylalanines. We found that the Y469F and Y645F mutants
were active (Fig. 2B), indicating the importance of the phenyl ring, but
not of a hydroxyl group at these positions for protein function.
3.3. Effects of cholesterol on the ATPase activity of the CRAC mutants
To test whether the CRAC tyrosine mutants are sensitive to the
cholesterol content of the membranes, we characterized their ATPase
activity in cholesterol-enriched insect cell membranes (Fig. 2C). The
cholesterol content of the insect cell membranes is relatively low, as
compared to mammalian cells (5–8 μg cholesterol/mg membrane
protein vs. 50 μg cholesterol/mgmembrane protein in insect andmam-
malian cells, respectively). Co-incubation with cholesterol-loaded cy-
clodextrin complexes was shown to be a reliable experimental tool to
increase the cholesterol contents of Sf9 membranes by up to 10-fold
[15]. Using this approach, we have shown that the ATPase activity, espe-
cially the activation of ATP hydrolysis by transported substrates, in the
case of the wild-type ABCG2 is greatly enhanced when the Sf9 mem-
branes are enriched in cholesterol (see [15] and Figs. 2C and 3A).
We found that the basal ATPase activity of the Y469F, Y570S and
Y645F mutants showed a moderate (approximately 20%, p b 0.05)
Fig. 1. Topologymodel of human ABCG2 indicating the positions of tyrosinesmutated in this study and also showing sequence alignment of human ABCG proteins. Protein sequences of
human ABCG proteins (ABCG2 AAG52982.1, ABCG1 P45844.3, ABCG4 NP_001135977.1, ABCG5 AG40003.1, ABCG8 AAG40004.1) were aligned using Clustalw (https://www.ebi.
ac.uk/Tools/msa/clustalw2/). Putative CRAC motifs are underlined; the 3 conserved amino acids in CRAC motifs are labeled with bold letters. The 2D structure was drawn by
using http://emboss.bioinformatics.nl/cgi-bin/emboss/topo based on the topology created by CCTOP (http://htp.enzim.hu/?_=/viewer/HTP_002649) [42,43].
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hydrolysis of the same mutants was signiﬁcantly (50–100% increase,
p b 0.01) accelerated by cholesterol loading (Fig. 2C). Therefore, these
CRAC mutants behaved similarly to the wild-type ABCG2 protein.
These results argue against a role of tyrosines 469, 570 and 645 in cho-
lesterol-sensing, suggesting that the corresponding regions are not
functional CRAC motifs.
Conversely, we found that in the presence of cholesterol, the ATPase
activity of ABCG2-Y413S was distinct from that of the wild-type trans-
porter. In the case of Y413S, cholesterol resulted in a major (50 +/−
8%; p b 0.01) enhancement of the basal ATP hydrolysis, which could
be only slightly stimulated by the addition of prazosin or quercetin
(Figs. 2B and C, and 4B).
Next, we investigated whether other compounds which are known
substrates of wtABCG2 also differently modify the Y413S-ATPase in
the presence of cholesterol (Fig. 3). Again, cholesterol potentiated the
drug-stimulated ATPase activity of the wild-type protein (Fig. 3A), as
well as the 469F, the 570S and 645F mutants in the presence of several
substrates (Supplementary Fig. S1). In contrast, the Y413Smutant had a
signiﬁcantly altered ATPase modulation pattern. Quercetin showed a
30 +/− 6.5% stimulation (p b 0.01), whereas doxorubicin, ﬂavopiridol,
topotecan and SN-38 resulted in a concentration dependent inhibition
(ranging from 26–70%) of the ATPase activity of the protein (Fig. 3B, C,
D and not shown).
For a detailed analysis of the effects of cholesterol loading, the
basal and drug-stimulated ATPase activities of the wild-type and
Y413S ABCG2 mutants were compared at increasing membrane cho-
lesterol concentrations. As shown in Fig. 4A, the baseline ATPase of
Y413S is activated by lower cholesterol concentrations than that ofthe wild-type protein, with a lower apparent half-maximum choles-
terol activation concentration (KA value of 0.37 +/− 0.27 mM) as
compared to the apparent afﬁnity of the wild-type protein for cho-
lesterol (KA for cholesterol of 0.70 +/− 0.09 mM). In contrast, in
the case of the substrate-stimulated ATPase activities, wtABCG2
showed higher sensitivity to cholesterol loading (Fig. 4B): in the
presence of quercetin the calculated KA value for cholesterol activa-
tion of the wild-type protein was 0.22 +/− 0.20 mM, while, due to
the low level of cholesterol activation a reliable KA for the Y413S pro-
tein could not be determined.
3.4. Altered bile acid sensitivity of the ABCG2-Y413S mutant
The experiments described above showed that both the baseline and
the drug-stimulated ATPase activity of the Y413S mutant differ signiﬁ-
cantly from that of the wild-type protein when excess cholesterol is
present. We have recently found that bile acids (steroids formed from
cholesterol in the liver) signiﬁcantly decrease the high basal ATPase ac-
tivity of wtABCG2, while they do not interfere with the ABCG2-
mediated ATP hydrolysis measured in the presence of substrates [16,
19]. This phenomenon results in a signiﬁcant (up to 5- to 7-fold) in-
crease in the relative, substrate stimulated ATP hydrolysis, depending
on the type of the bile acid. In order to ﬁnd out whether the active
ABCG2 CRAC mutants have any alterations in their interactions with
bile acids, we measured their ATPase activities in the presence of cholic
acid, glycocholate and taurocholate.
We found that the ATPase activities of the 570S, 469F, 645F and
wild-type ABCG2 variants were similarly modiﬁed by bile acids (data
not shown). In contrast, we found major differences in the effects of
Fig. 2.Expression andATPase activity of ABCG2 CRAC tyrosinemutants in Sf9 insect cells. Panel A: Expression of CRACmutants in Sf9membranes. Sf9membranes expressingwtABCG2 and
its Tyrmutants were subjected to Laemmli gel electrophoresis. ABCG2was visualized by the BXP-21 antibody. Panels B and C: ATPase activity of ABCG2-CRACmutants in Sf9 insectmem-
branes. Vanadate-sensitive ATPase activity was measured in non-treated (labeled as control, Panel B) insect membranes or in insect membranes loaded with 2 mM cholesterol-RAMEB
(Panel C) during the membrane preparation (see Section 2.6.) in the absence of added compounds (baseline), or in the presence of 1 μM quercetin, 100 μM prazosin or 1 μM Ko143.
Bars show the average of at least two independent experiments, each measured in two parallels, +/− S.D. values.
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tion of bile acids decreased the baseline ATPase activity of this ABCG2
mutant (Fig. 5A), bile acids also decreased ATP hydrolysis in the pres-
ence of substrates. Therefore the net result of bile acid effects was only
a slight increase in the relative substrate stimulation of the Y413S mu-
tant (Fig. 5B–D).3.5. Effects of cholesterol on the transport activity of the ABCG2 CRAC
mutants in Sf9 membranes
In addition to its effect on theABCG2-ATPase activity, cholesterol has
also been shown to signiﬁcantly enhance the transport capacity of the
protein – e.g. methotrexate transport by the wild-type ABCG2 was
Fig. 3. Effect of known wtABCG2 substrates on the ATPase activity of wtABCG2 and the Y413S mutant. Vanadate-sensitive ATPase activity was determined in 2 mM cholesterol-RAMEB
treated membranes in the absence of substrates (baseline) or in the presence of 5 μΜ quercetin, 50 μΜ doxorubicin, 20 μΜ SN-38, 50 μΜ ﬂavopiridol or 50 μΜ topotecan (Panels A
and B). ATPase activity was also determined in the presence of increasing concentrations of doxorubicin or topotecan (Panels C and D). Figure shows the result of three indepen-
dent experiments, +/− S.D. values.
482 Z. Gál et al. / Biochimica et Biophysica Acta 1848 (2015) 477–487about 4-fold activated when the insect cell membrane vesicles were
enriched in cholesterol [15]. To further analyze the consequence
of the putative CRAC Tyr mutations on the cholesterol-sensing of
ABCG2, we measured 3H-methotrexate transport both in control and
cholesterol-loaded Sf9 membrane vesicles. As documented in Fig. 6, all
the examined ABCG2mutants, including Y413S, exhibited amethotrex-
ate transport activity that, similarly to the wild-type transporter, was
signiﬁcantly (3- to 4-fold) enhanced by cholesterol loading of the
membranes.Fig. 4.Effect of cholesterol on thewtABCG2and Y413S-ATPase. Vanadate-sensitive ATPase activi
0.25–2 mM cholesterol-RAMEB to achieve various membrane cholesterol levels. ATPase activi
quercetin (Panel B). The average of four independent experiments +/− S.D. values are shown3.6. Expression and transport activity of ABCG2 CRAC mutants in HEK 293
cells – effect of cholesterol depletion
According to the presented results the baselineATPase activity of the
ABCG2-Y413S mutant showed a sterol sensitivity that signiﬁcantly
differed from that of the wild-type protein, while in the vesicular trans-
port measurement the effect of cholesterol on this mutant did not differ
from that measured for wtABCG2. In order to further characterize the
“cholesterol-dependence” of the CRAC mutant ABCG2 proteins, wetywasdetermined as described in Section 2.9. Controlmembraneswere co-incubatedwith
ty was measured in the absence of added substrates (Panel A) or in the presence of 5 μM
. *Student's t-test, signiﬁcant difference, p b0.05.
Fig. 5. Effect of bile acids on thewtABCG2and Y413S-ATPase. ATPase activitywas determined in Sf9membrane vesicles loadedwith 2mMcholesterol-RAMEB. Panel A: Vanadate-sensitive
basal (no added substrate) or 1 μM quercetin-stimulated ATPase activity in the absence or presence of 1 mM glycocholate (GC), 1 mM cholic acid (CA) or taurocholate (TC). Panel B: Rel-
ative ATPase activity in the presence of 1 μMquercetin compared to the baseline is shown against increasing bile acid concentrations. Experiments were performed in quadruplicates, av-
erage +/− S.D. values are shown.
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Y469F, Y570S and Y645Fmutants. Western blotting conﬁrmed success-
ful expression of these proteins (data not shown). Moreover, labeling
with the anti-ABCG2 5D3 antibody, which recognizes an extracellular
epitope, indicated proper plasma membrane localization of these
mutants (Supplementary Fig. S2).Fig. 6. Transport of 3H-methotrexate into control and cholesterol-loaded inside-out Sf9 in-
sect membrane vesicles. Intravesicular accumulation of 50 μM 3H-methotrexate in Sf9
membrane vesicles with different ABCG2 mutants containing 90 μg of total membrane
protein was measured at 37 °C for 10 min in the presence or absence of 1 μM Ko143. For
the investigation of the effect of cholesterol, themembranes were loadedwith 2mM cho-
lesterol-RAMEB. Control represents non-loaded membranes. Bars represent average
Ko143-dependent transport obtained in two independent experiments, each with two
parallels +/− S.D. values.To characterize the effect of cholesterol on the ABCG2 transport
function, we depleted the cholesterol content of the cells by co-
incubation with cyclodextrin (RAMEB). This method decreases mem-
brane cholesterol levels by about 25%, and was successfully used in ear-
lier studies to deﬁne the effects of various cholesterol levels on ABCG2
function in mammalian cells [15,33]. Previously we have demonstrated
that mild cholesterol depletion of HEK 293 cells resulted in a decreased
transport function of wtABCG2, while did not alter the localization of
ABCG2 or the viability of the cells [15].
For measuring ABCG2 transport activity, intracellular accumulation
of Hoechst 33342 was followed in control and cyclodextrin-treated
HEK 293 cells, expressing the wild-type and the CRAC mutant ABCG2
proteins. As shown in Fig. 7, all ABCG2 mutants, including Y413S, were
able to actively transport Hoechst 33342, and cholesterol depletion sig-
niﬁcantly decreased the Hoechst 33342 transport activity of all the
CRAC mutants similarly to wild-type ABCG2.
3.7. Putative CRACmutants of ABCG2, including Y413S, effectively transport
substrate drugs and protect HEK 293 cells against cytotoxic substrates
The differential effect of the transported substrates on thewild-type
and the Y413S ABCG2 ATPase activity may reﬂect different transport
properties. Still, we did not ﬁnd any alteration of the transport capacity
or the cholesterol sensitivity of theHoechst 33342 transport in the CRAC
mutants.
In order to further explore the relationship of altered drug-
stimulated ATPase and transport activities, the transport of variousﬂuo-
rescent ABCG2 substrates was compared in HEK 293 cells overexpress-
ing wtABCG2 and the Y413S mutant, respectively. No major difference
was found in BODIPY-prazosin, Hoechst 33342, mitoxantrone and
Pheophorbide A transport by any of the active mutants analyzed in
Fig. 7.Hoechst 33342 transport in ABCG2-expressing HEK 293 cells – effect of cholesterol
depletion. HEK 293 cells stably expressing wtABCG2 and its mutants were incubatedwith
2 μMHoechst 33342 for 20 min at 37 °C with or without 1 μM Ko143. After washing, cel-
lular ﬂuorescence of Hoechst 33342 was determined by ﬂow cytometry. Cholesterol de-
pletion was achieved by co-incubation of the membranes with empty cyclodextrin (see
2.12.); control values show results obtainedwith non-treated cells. Transport factor in liv-
ing (propidium-iodide negative) cells was calculated as described in Section 2.11. Experi-
ments were performed in quadruplicates; bars show the average of at least three
independent measurements +/− S.D. values.
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ATPase assay, the Y413Smutant also did not differ signiﬁcantly from the
wild-type protein, with respect to the transport of the abovementioned
substrates.
Among the cytotoxic drugs, the Y413S mutant ABCG2 protein (sim-
ilarly to the wild-type) was able to transport doxorubicin (Fig. 8A) and
provided protection against doxorubicin, SN-38, ﬂavopiridol and
topotecan, strongly indicating an active transport of these compounds
by this mutant (Fig. 8B and Supplementary Fig. S3).
4. Discussion
Understanding the regulation of the expression and function of
ABCG2may have important implicationswith regard to themodulation
theADME-Tox parameters of drugs and xenobiotics, in anti-cancer ther-
apies, aswell as in the treatment of gout. Cholesterol has been shown to
be an essential activator of ABCG2 function [14–16], although the exact
nature of the interaction between cholesterol and the transporter has
not yet been deﬁned. Also, the molecular determinants of cholesterol-
sensing byABCG2 remain largely unknown [19,20]. Cholesterol recogni-
tion amino acid consensus sequence (CRAC) motifs have previously
been conﬁrmed to be involved in cholesterol-sensing of various pro-
teins [21–25,34,35]. Site directed mutagenesis studies targeting con-
served CRAC amino acids identiﬁed a large variety of protein-speciﬁc
phenotypes. In the case of the HIV gp41 protein, CRACmutations result-
ed in reduced cholesterol binding [35]; mutant peripheral-type benzo-
diazepine receptor variants showed altered cholesterol transport [34],
while in ion channels the channel function was retained but regulation
by cholesterol was abolished [25,36].
Here, we aimed to determine whether the CRAC motifs identiﬁed in
the ABCG2 sequence play any role in the sterol-sensing of the human
ABCG2 multidrug transporter. We found ﬁve putative CRAC sequencesTable 1
All active Tyr mutants are able to transport various known ABCG2 substrates. Ko143-sen-
sitive transport was determined in HEK 293 cells expressing one of the ABCG2 variants.
BODIPY-prazosin Pheophorbide A Hoechst 33342 mitoxantrone
wtABCG2 + + + +
Y413S + + + +
Y469F + + + +
Y570S + + + +
Y645F + + + +located in or near the transmembrane helices of ABCG2 (Fig. 1). Based
on the previous CRACmutagenesis studies described above, we expect-
ed that mutation of a functional CRAC motif would modify the effect of
cholesterol on ABCG2 function. We have approached this question by
using a number of speciﬁc methods.
ABC transporters couple ATPase and transport activities to promote
the transmembrane movement of their substrates. This complex enzy-
matic activity can be followed in several experimental systems. ABCG2
expressed in Sf9 membranes displays relatively high baseline ATPase
activity that can be moderately stimulated by transported compounds.
The low intrinsic cholesterol content of the insect cell membrane
allows the systematic modulation of membrane cholesterol levels.
Using this model system, we and others have shown that the
substrate-stimulated ATPase activity of ABCG2 is signiﬁcantly accel-
erated by cholesterol [14,15]. Cholesterol makes up to 20% of the
total lipids in mammalian cell membranes. Partial cholesterol depletion
can be achieved by using “empty” cyclodextrins, which has been shown
to result in a decrease of ABCG2 transport activity [15,33]. Using this
repertoire of assays we aimed to determine the role of the identiﬁed
ﬁve CRAC motifs in the cholesterol-sensitive functions of ABCG2.
We found that tyrosines of putative CRAC motifs predicted to be
located in or near to the intracellular surface of ABCG2 (Fig. 1) are essen-
tial for protein expression and/or function. Tyr to Ser mutations at posi-
tions 459, 469 and 645 resulted in the loss of protein function, and the
Tyr 459 to Sermutation resulted in a complete loss of ABCG2 expression
(Fig. 2). Insect cells are cultured at 27 °Cwhich has been shown to allow
the expression of improperly folded proteins [37]. The fact that the
Y459S mutant could not be expressed properly in insect cells suggests
that the tyrosine at this amino acid position is crucial for the proper
folding and processing of the protein and therefore might be an impor-
tant determinant of ABCG2 structure. Recently, the Y459C heterozygous
mutation was reported to occur in patients with renal cancer [38].
Therefore further exploration of the effect of mutations to residue 459
in ABCG2 is warranted.
The Y469S and Y645S mutants could be expressed in comparable
amounts to the wild-type protein, however, they were found to be
non-functional (Fig. 2). These results may be interpreted in two ways.
First, these tyrosines may be important for proper function or, alterna-
tively, these mutants may lose their cholesterol-sensing capability. In-
terestingly, introduction of a phenyl residue at the same position was
found to be compatible with normal ATPase and transport activity, as
well as with cholesterol-sensing, indicating that these regions are not
functional CRAC motifs. Rather, Y469 and Y645, along with Y459, may
be important for proper folding of ABCG2. Our experiments, in which
we tested the conformation of the ABCG2 mutants by labeling them
with the conformation sensitive anti-ABCG2 5D3 antibody, revealed
that theY469S andY645Smutants have decreased 5D3 binding capacity
(Supplementary Fig. S4). Therefore the loss of the activity of the Y469S
and Y645S mutants is most probably due to their improper conforma-
tion and not by their altered cholesterol-sensing.
Previously, the Y645F mutation has been found to be functional, al-
though has shown slightly decreased Hoechst 33342 transport capacity
[39]. Interestingly, we did not ﬁnd anymajor alteration in the substrate
recognition by this mutant. Even its Hoechst 33342 transport capacity
did not differ signiﬁcantly from that of the wild-type protein (Fig. 7).
The other two tyrosines (Y413 and Y570) mutated in this study are
located in or near the extracellular surface of the transmembrane do-
main. We found that changing these amino acids is well tolerable for
ABCG2, resulting in fully active proteins. The Tyr 570 to Ser mutation
did not alter protein expression either in Sf9 or in HEK 293 cells, and
substrate recognition and cholesterol-sensing of this mutant was also
similar to that of the wild-type transporter (Figs. 2 and 6 and Supple-
mentary Fig. S1).
However, the Y413Smutant exhibited a distinct ATPase activity. This
mutant showed a greatly increased baseline ATPase in the presence of
low levels of added cholesterol (Fig. 4A), revealing an increased
Fig. 8. Panel A: Doxorubicin efﬂux from HEK 293 cells. Doxorubicin (5 μΜ) efﬂux was measured as described in Section 2.13. Fluorescence of the cells was monitored by ﬂow cytometry.
Experiments were performed in duplicates. Figure shows representative graphs. Panel B. Cytotoxicy of ABCG2 substrates in HEK 293 cells. HEK 293 parental cells or stably expressing
wtABCG2 or its Y413S mutant were incubated with 50 nM SN-38, 50 nM topotecan (TOP), 60 nM doxorubicin (DOX) or 500 nM ﬂavopiridol (FLP) for 72 hours. Cell viability was deter-
mined by PrestoBlue staining. 100% represents cells incubated at the same conditions in the absence of any drugs. Bars show the average of four independent experiments with quadru-
plicates each, +/− S.D. values.
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ATPase could be achieved by administration of transported substrates
regardless of the cholesterol content of the membrane. Moreover, po-
tential substrates that are known to activate the wild-type ABCG2-
ATPase, rather inhibited the ATPase activity of the Y413S mutant
(Fig. 3). In addition to this altered cholesterol-sensing, the ATPase activ-
ity of the Y413S mutant also showed an altered bile acid sensitivity, as
this mutant was less sensitive to bile acids than the wild-type protein
(Fig. 5).
The nature of the relatively high baseline ATPase activity of the
human ABCG2 transporter is still not clariﬁed. One explanation is an
intrinsic, partially uncoupled function of the protein, manifesting in a
“futile” ATP hydrolysis, keeping this multidrug transporter alert for
rapid export of potentially harmful compounds [40]. Another possibility
is the presence of an endogenous transported substrate, potentially cho-
lesterol, triggering ATP hydrolysis without the addition of exogenous
compounds. In the case of the Y413S mutant, cholesterol may promote
“uncoupling” of the ATP hydrolysis in the ABCG2 protein. Alternatively,
if we consider the possibility that cholesterol is transported by ABCG2,
the results could be explained by a higher afﬁnity to cholesterol by the
ABCG2-Y413S mutant, also observed in the case of the R482G mutant
[15]. The cholesterol-dependent increase in the ATPase activity is simi-
lar to that observed for several transported substrates. If ABCG2 can
transport cholesterol, our data can be interpreted to suggest that the
Y413Smutant is amore efﬁcient cholesterol transporter. Unfortunately,
experimental veriﬁcation of cholesterol transport is difﬁcult due to
the lack of dedicated assays measuring ABCG2-mediated cholesterol
transport. Tarling et al. [41] measured cholesterol efﬂux to HDL in
ABCG1 and ABCG2 overexpressing cells, and found that, in contrast to
ABCG1, ABCG2 is not able to transport cholesterol to HDL. Since
ABCG2-mediated cholesterol transport has not been experimentally
conﬁrmed, we speculate that the “cholesterol-stimulated”ATPase activ-
ity of the ABCG2-Y413Smutant is a result of its differential sensitivity to
the modulatory effect of cholesterol.
In contrast to these ﬁndings related to the ABCG2-ATPase activity,
we did not ﬁnd any signiﬁcant alteration in the cholesterol sensitivity
of the ABCG2-Y413S mediated transport either in insect cell vesicular
transport, or mammalian intact cell transport assays. Active substrate
transport by the Y413S mutant was clearly activated by cholesterol in
both systems, and by all the compounds examined (Figs. 6 and 7).
Moreover, the Y413S mutant protected the cells against toxic drugs
similarly to the wild-type ABCG2. All these experimental data suggest
that although the ABCG2-Y413S mutant has an altered cholesterol in-
teraction, it is rather manifested in a partial uncoupling of the ATPase
activity of the transporter in the absence of transported substrates.
5. Conclusions
Our study is the ﬁrst detailed analysis of potential CRACmotifs with-
in an ABC protein, and here we provide experimental data for various
functional consequences of the mutations in these motifs in ABCG2.
Surprisingly, none of the functional CRAC mutants analyzed here
abolished the cholesterol-sensitivity of the transporter, although muta-
tion of Y413 signiﬁcantly affected cholesterol and bile acid interactions.
These data suggest that Tyr 413 within a putative CRAC motif is most
probably part of a sterol-dependent regulatory region of ABCG2 and
may regulate the coupling of ATPase to transport activity.
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